CMPX.US Compass Therapeutics Inc.

Healthcare Biotechnology USA Stocks
0.7738 USD
Close of Nov 14, 2026
0.6714 6.88
Market cap
USD 139M
P/E
-
P/B
1.04x
ROE
-66.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CMPX.US undervalued?

Graham number

The Graham number of Compass Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Compass Therapeutics Inc. fundamental analysis

No fundamental analysis for Compass Therapeutics Inc. yet.

Compass Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Compass Therapeutics Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that i…

Full company profile